Vimarsana
Biggest News Aggregation in the World

Page 24 - Fda Approval News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Fda Approval. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Fda Approval Today - Breaking & Trending Today

AstraZeneca's Tagrisso accepted and granted priority review in US - Vimarsana News

AstraZeneca's Tagrisso accepted and granted priority review in US

AstraZeneca’s supplemental new drug application (sNDA) for lead lung cancer drug Tagrisso (Osimertinib) in combination with chemotherapy has been accepted and granted priority review in the US.

Addressing Healthcare Inequity With Accessible Multicancer Early Detection - Vimarsana News

Addressing Healthcare Inequity With Accessible Multicancer Early Detection

The potential of MCED testing to reduce health inequities and an examination of accessibility, including FDA approval, physician education, patient awareness, affordability, and logistical support.

South Rampart Pharma Receives U.S. FDA Fast Track Designation for SRP-001 for Acute Pain - Vimarsana News

South Rampart Pharma Receives U.S. FDA Fast Track Designation for SRP-001 for Acute Pain

/PRNewswire/ -- South Rampart Pharma, Inc. ("South Rampart" or the "Company"), a clinical-stage biopharmaceutical company targeting the safer treatment of...

Cellipont Bioservices and Diakonos Oncology Corporation Collaborate to Develop Groundbreaking Therapy for Glioblastoma - Vimarsana News

Cellipont Bioservices and Diakonos Oncology Corporation Collaborate to Develop Groundbreaking Therapy for Glioblastoma

/PRNewswire/ -- Cellipont Bioservices, a leading CDMO in cell therapy development and manufacturing and Diakonos Oncology, announced today that they have...

Kyowa acquiring gene therapy firm Orchard for up to $478M - Vimarsana News

Kyowa acquiring gene therapy firm Orchard for up to $478M

Japanese specialty global pharma Kyowa Kirin Co. Ltd. has agreed to buy out Orchard Therapeutics plc in a $387.4 million cash takeover that could jump $90 million to reach $477.6 million, contingent on the pending U.S. FDA approval of its EU-approved gene therapy, Libmeldy (atidarsagene autotemcel).